


Product Name : Zotiraciclib
Cat. No. : PC-38758
CAS No. : 937270-47-8
Molecular Formula : C₂₃H₂₄N₄O
Molecular Weight : 372.46
Target : Cyclin-dependent Kinase (CDK)
Solubility : 10 mM in DMSO



Biological Activity

Zotiraciclib (TG02, SB1317) is a potent multi-kinase inhibitor of cyclin dependent kinases (CDKs), JAK2, and FLT3 with IC₅₀ of 13, 73, and 56 nM for CDK2, JAK2 and FLT3, respectively.

Zotiraciclib (TG02, SB1317) is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.

Zotiraciclib (TG02, SB1317) shows high sensitivity to primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients.

Zotiraciclib (TG02, SB1317) exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.

Zotiraciclib (TG02, SB1317) also shows oral efficacy in colon (HCT-116) and lymphoma (Ramos) xenografts.

References

Ortiz-Ruiz MJ, et al. *Oncotarget*. 2014 Nov 30;5(22):11308-18.

Poulsen A, et al. *J Mol Model*. 2013 Jan;19(1):119-30.

William AD, et al. *J Med Chem*. 2012 Jan 12;55(1):169-96.

Goh KC, et al. *Leukemia*. 2012 Feb;26(2):236-43.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com